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GENERAL INTRODUCTION INTO THE EBOLA VIRUS  
BIOLOGY AND DISEASE
Abstract: Epidemic of Ebola hemorrhagic fever which appeared in the countries of West Africa in 
2014, is the largest outbreak which occurred so far. The virus causing this epidemic, Zaire Ebolavirus 
(ZEBOV), along with four other species of Ebolaviruses is classified to the genus Ebolavirus in the 
family Filoviridae. ZEBOV is one of the most virulent pathogens among the viral haemorrhagic fevers, 
and case fatality rates up to 90% have been reported. Mortality is the result of multi-organ failure 
and severe bleeding complications. The aim of this review is to present the general characteristics 
of the virus and its biological properties, pathogenicity and epidemiology, with a focus on laboratory 
methods used in the diagnosis of these infections.
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INTRODUCTION
The epidemic of Ebola haemorrhagic fever (now called Ebola virus disease) ob-
served in 2014 in West Africa is the largest outbreak which occurred since the 
first case of this disease in 1976. The number of cases and deaths has already 
exceeded the number of recorded cases in all previous epidemics together. Accord-
ing to the WHO report of November 21, 2014, the total number of confirmed or 
suspected cases in the current outbreak is 15,351, with 5,459 reported deaths. 
Guinea, Liberia and Sierra Leone are the most affected countries [1]. The aim of 
the review is to present the characteristics and biology of the virus responsible 
for this haemorrhagic fever, the sources of infection and clinical feature of dis-
ease, as well as a possible methods of diagnosis.
TAXONOMY
According to the recently announced taxonomy of viruses, Ebolavirus belongs 
to order — Mononegavirales, family — Filoviridae, and genus — Ebolavirus with 
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5 identified species: Bundibugyo Ebolavirus (BEBOV), Reston Ebolavirus (REBOV), 
Sudan Ebolavirus (SEBOV), Tai Forest Ebolavirus (formerly Ivory Coast Ebolavirus, 
ICEBOV), Zaire Ebolavirus (ZEBOV).
In addition to the genus Ebolavirus, family Filoviridae includes two other gen-
era: Cuevavirus and Marburgvirus [2]. The filoviruses are primarily African in or-
igin, with the exception of Reston virus and recently identified in Spanish bats 
Lloviu virus, which represents distinct Cuevavirus genus.
Virus name is derived from the Ebola River in the Democratic Republic of Con-
go (formerly Zaire), where the first cases of haemorrhagic fever were recorded in 
1976. The disease was observed simultaneously in southern Sudan, and in the 
northern Zaire, and now it is known that it was caused by two different species 
SEBOV and ZEBOV, respectively. The name of the family Filoviridae comes from 
the Latin word “filum” or thread, because the virion shape resembles a twisted 
thread when viewed under an electron microscope [3, 4].
Among the viruses of the Ebolavirus genus, ZEBOV has the highest fatality 
rate (up to 90%). In case of infection with other species this ratio is significantly 
lower (approx. 53% and 25%, respectively for SEBOV and BEBOV). Sick people 
or contact with human corpses are the main sources of infection during an ep-
idemic, but the natural reservoir of the virus are probably asymptomatic infect-
ed fruit bats, whose isolates of filoviruses are characterized by very high genetic 
diversity [5, 6]. Phylogenetic analyses of Marburg virus RNA sequences derived 
from both, people and bats, suggest that the virus spread from bats might gen-
erate an epidemic in humans [7]. In addition, macaques, chimpanzees, antelopes, 
rodents and other so far unidentified species may represent a significant source 
of infection for humans.
Sudan Ebolavirus (SEBOV) isolated from humans in Nzara in southern Su-
dan most likely does not have animal reservoir. This assumption is justified by 
the territorially limited occurrence and genetic stability of strains originated from 
neighboring Sudan and Uganda for almost 30 years [6]. In 1994, Tai Forest Eb-
olavirus (TAFV) was isolated in the Ivory Coast from an ethnologist making the 
autopsy of chimpanzee from the Tai National Park reserve. Because it has been 
described only in a single nonfatal human case, therefore was assumed to infect 
mainly chimpanzees.
Ebola-Bundibugyo virus (BEV) appeared in 2007. The name Bundibugyo virus 
comes from the town in Uganda. BEV infection cannot be differentiated from 
other ebolaviruses by clinical symptoms. Further, the Reston Ebolavirus (REBOV) 
originates from the Philippines. It was first detected in Reston, VA, USA, in ma-
caques imported from the Philippines and housed at a quarantine facility. This 
species caused in nonhuman primates haemorrhagic fever with high mortality. 
It also emerged in Philippines pigs, usually co-infected with porcine respiratory 
and reproductive virus (PRRS), but the actual pathogenic potential of REBOV in 
pigs remains unclear. It is known to be non-pathogenic to humans, although the 
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presence of specific antibodies in humans suggests the possibility of its transfer 
from infected animals [4].
SENSITIVITY TO PHYSICAL AND CHEMICAL AGENTS
Ebola viruses are classified as both biosafety level 4 and category A list patho-
gens. Currently, there are no approved options available for either treatment or 
postexposure prophylaxis. Filoviruses infectivity is quite stable at room tempera-
ture, but is largely inactivated by 30 minute incubation at 60oC. Current methods 
inactivating filoviruses are limited to high doses of ultraviolet light and gamma 
irradiation, formalin treatment, lipid solvents, b-propiolactone, photo-induced al-
kylating probe 1,5-iodonaphthylazide, and commercial hypochloride and phenolic 
disinfectants [8, 9].
VIRION STRUCTURE
The virion has a uniform diameter of about 80 nm, and the length from 970 to 
1200 nm. When propagated in cell cultures it is characterized by a significant 
pleomorphism and its length can then increase up to 14,000 nm [10]. The viri-
on core contains one molecule of linear, non-segmented, single-stranded, nega-
tive-sense RNA. The RNA is helically wound and complexed with the NP, VP35, 
VP30, and L proteins. The helical nucleocapsid is surrounded by an outer enve-
lope with anchored specific glycoprotein (GP) spikes, of about 10 nm length. These 
glycoproteins play a key role in the pathogenesis, due to the role in virus entry 
and its immunogenicity. Glycoproteins are targets for the immune cells, and thus 
are taken into account in the development of vaccines. Viral matrix protein, VP40 
and VP24, are located between the nucleocapsid and the outer envelope (derived 
from the host cytoplasmic membrane). The viral genome, approximately 19 kb in 
length, is the longest among all viruses belonging to the order Mononegavirales. 
Sequentially arranged genes encode seven structural proteins, respectively 3’-nu-
cleoprotein (NP), polymerase cofactor (VP35), matrix protein (VP40), glycoprotein 
(GP), protein VP30, matrix protein (VP24), RNA-dependent RNA polymerase (L) 
and one non-structural small glicoprotein — sGP, the function of which is not 
yet completely understood. This small glycoprotein is not a part of the virion, but 
is excreted from the infected cell in large quantities. It may play a role in con-
founding the immune system to prevent the marshaling of an effective immune 
response. Moreover, viral proteins VP24 and VP35 are also important virulence 
factors, because they act as a type I interferon (IFN) antagonists [4, 11].
The 3’ terminus of viral genome is not polyadenylated and the 5’ end is not 
capped. The leader and trailer at the 3’- and 5’- ends are non-transcribed regions, 
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but they carry important signals to control transcription, replication, and pack-
aging of the viral genomes into new capsids. Sequences encoding the viral struc-
tural proteins contain open reading frames and are flanked by the non-translated 
intergenic regions.
REPLICATION
The first step in viral replication is attachment to the host cell membrane and 
penetration into the cell. This process is not completely understood, but it is 
known that glycoprotein (GP) spikes are involved in entry of virions into the host 
cell and are used in the mechanisms similar to macropinocytosis [12]. The oth-
er proposed mechanisms of cell entry include: clathrin-mediated endocytosis or 
glycoprotein-facilitated receptor binding. The glycoprotein is posttranscriptionally 
cut into GP1 and GP2 proteins. The GP1 takes part in the attachment of the vi-
rus particle to the cell membrane, while the GP2 participates in viral fusion with 
the cell membrane. Viral membrane fuses with cell vesicle membrane to allow 
the release of the nucleocapsid into the cytoplasm. It is believed that the fur-
ther steps of replication occur in the cytoplasm, analogously to paramyxoviruses 
and rhabdoviruses. Encapsidated, genomic RNA is used then as a template for 
transcription into seven polyadenylated, monocistronic mRNAs and translated by 
the cellular translation machinery into individual viral proteins. Transcription is 
regulated by conserved transcription start and stop signals located at the viral 
gene borders. The gene start signals are parts of RNA secondary structures, and 
it has been proposed that VP30 binds to the RNA at the first gene start signal 
to initiate transcription. In addition, VP30 was shown to be important for reiniti-
ation of transcription of subsequent genes [13]. VP30 activity is regulated via its 
phosphorylation state: phosphorylation of VP30 inhibits viral transcription while 
viral replication is increased. Because of its essential function in these processes, 
VP30 is a potential interesting candidate as antiviral therapy target [3]. 
Subsequently, when a positive-sense full-length genome is replicated, it is con-
comitantly encapsidated by newly synthesized NP molecules. Other structural nu-
cleocapsid proteins (polymerase cofactor — VP35, and the viral RNA polymerase L) 
participate in the synthesis of the viral genome. The presence of matrix VP24 
together with NP and VP35 is required for assembly of viral nucleocapsids, and 
silencing of VP24 expression prevents the release of viruses. Moreover, in the 
VP24-deficient viral particles VP30 transcription and translation are diminished 
[14]. Further, the most abundantly expressed matrix protein VP40 plays an im-
portant role in the formation of new virus particles, and is associated with the 
endosomal pathway and virus budding from the cell [15]. The mechanisms of this 
process are not fully understood but it is known that mutations in the sequences 
encoding the VP40 leads to inhibition of virus release from the infected cell.
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CLINICAL MANIFESTATION AND PATHOGENESIS OF EBOLA VIRUS  
HAEMORRHAGIC FEVER
All filovirus infections of human are characterized by a similar disease, which 
severity and fatality rate depends on infecting viral species. Pathomechanism of 
Ebolavirus infection is complex. It involves phagocytic cells, released proinflam-
matory cytokines, chemokines, and growth factors, endothelial cell dysfunction 
and triggering of coagulopathy, direct damage of cells by viral replication as well 
as suppression of innate and adoptive immune response [16].
The symptoms of the disease appear after 4–10 days of incubation period 
(range 2–21 days, depending on the infective dose). Typical is the sudden onset 
of flu-like symptoms, vomiting and diarrhea. The patient’s condition deteriorates 
rapidly and the next phase of the disease results from external and internal 
bleeding complications, hypotension and coagulation disorders, and often leads to 
fulminant shock and subsequent multi-organ failure. Fully symptomatic patients 
usually die between 6–16 days after onset of symptoms. In cases of recovery, 
the patient’s clinical condition was improved with the appearence of specific anti-
bodies. However, long-term consequences of infection may persist as a recurrent 
hepatitis, spinal cord injury, uveitis, psychosis or hair loss [17, 18].
Existing data on the pathological mechanism involved in the disease have been 
obtained by experimental infection of non-human primates and rodents as well 
as by clinical and laboratory observation collected during the human outbreaks. 
The virus enters the body parenterally, through the skin and mucous mem-
branes. It exhibits a broad tropism to different cells. This apparent lack of target 
specificity is probably due to the wide distribution of cell-surface lectins involved 
in the binding of the viral surface GPs. Macrophages, monocytes, and dendritic 
cells are the early targets of viral infection. Due to their high migratory activity 
these cells play a key role in the spread of the virus from the initial site of in-
fection to the regional lymph nodes, liver, spleen and adrenal glands. 
Virus utilize multiple mechanisms to evade detection and undermine innate 
immune responses. The mentioned structural proteins VP24 and VP35 are crucial 
to evade host innate immunity and inhibit type I interferon responses [19]. The 
sGP protein inhibits the migration of leukocytes. Viral infection is accompanied 
by a massive release of proinflammatory mediators and vasoactive substances, 
which promotes inflammation and coagulation, but at the same time renders the 
immune system unable to effectively prevent systemic spread of the virus. 
Haemorrhagic effects of Ebolavirus infection in endothelial cells are likely trig-
gered by immune-mediated mechanisms. It has been hypothesized that Ebolavi-
rus VP40, GP1, and GP2 were able to activate endothelial cells and significantly 
impair the barrier function [3]. 
The coagulopathy is multifactorial and appears to be caused by a combination of 
activation of several factors, such as: the mononuclear phagocytic system, platelet 
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aggregation and consumption, activation of the coagulation cascade, deficiency 
of coagulation factors due to liver damage, and endothelial damage. Therefore, 
the cause of death may be either bleeding or blood clotting, frequently with multiple 
organ failure.
EPIDEMIOLOGY
Ebola virus disease is a zoonotic disease and each outbreak in the human popu-
lation is initiated by an introduction from an animal reservoir (e.g. due to hunt-
ing, direct contact with infected live or dead animals, consuming of bush meat). 
The spread of sporadic cases appearing among the rural population living near 
the rainforest, to the large urban agglomerations is responsible for the devel-
opment of a new epidemic. A leading source of infection is direct contact with 
a sick person (particularly in the late stages of infection, when viral loads are the 
highest) or contaminated objects used by the patient. Infection of healthcare work-
ers or those taking care of sick persons, in the absence of appropriate personal 
protective equipment, and during the funeral ritual are an important element in 
the epidemiological chain. Sexual transmission during convalescence stage was 
also described. Body fluids (mainly blood) and secretions (saliva, urine, vomit, 
feces, semen) are infectious. Filoviruses enter the host through mucosal surfac-
es, breaks, and abrasions in the skin, or by accidental injection. In hospital en-
vironment infection through the aerosols is also possible (e.g. during intubation, 
bronchoscopy), although there is no clear evidence that airborne spread from 
person to person occurs. In an animal model it was confirmed that in the case 
of needle-stick injury the risk of infection and disease progression is significantly 
greater than after administration of a similar dose by aerosol [20]. 
The current epidemic in West Africa, which was announced in March 2014, 
was preceded by the incidences already recorded in December 2013 in Forest-
ed Guinea. The causative agent has been identified as an outlier strain of Zaire 
Ebola virus [21]. Characteristic of the current ongoing epidemic mortality rate is 
much lower than that observed in previous outbreaks.
LABORATORY DIAGNOSTIC METHODS
Since the Ebola virus has been classified by the CDC as a pathogen of category 
A, the category that includes most dangerous pathogens causing diseases with 
high morbidity and mortality, viral diagnosis should be performed only in spe-
cialized laboratories with the highest level of biosafety, i.e. BSL-4.
It should be fast, sensitive and specific, and the methodology used should 
greatly limit the possibility of exposure of a person engaged in the study to the 
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risk of the laboratory infection. If the diagnostic methodology allows, chemical 
or radiation inactivation of clinical material should be used before testing. The 
selection of the tests is also dependent on the capabilities of performers being 
under different conditions, even at the site of the epidemic outbreaks.
Currently, real time RT-PCR is considered as the most sensitive method, which 
allows for detection of the number of viral copies in specimen. Although there 
are other methods of virus identification. But the presence of viral RNA can be 
detected by polymerase chain reaction with reverse transcription (RT-PCR) even 
after 48 hours post onset. However, it should be emphasized that due to contin-
uous virus mutations RT-PCR method may be unreliable and results should be 
confirmed by other assay. One-tube real-time RT-PCR assay was developed for 
identification of ZEBOV and SEBOV. To distinguish between Ebolavirus species 
and strains sequencing of amplified genomic RNA can also be used [22].
The enzyme-linked immunosorbent assay (ELISA) may be used to detect both 
antibodies as well as virus-specific antigens. Assays for the detection of antibodies 
are less useful because the patient often dies before the formation of a specific 
antibodies. Therefore, they are carried out mainly for epidemiological purpose, 
for patients who survived this terrible disease. Positive results obtained by the 
ELISA can be confirmed by Western blot. Sometimes only IgM antibodies are de-
tectable in specimen of sick person. They appear after 2 days of symptoms onset 
and may last for 30–168 days. In contrast, IgG antibodies usually are detected 
between day 6 and 18 post onset of illness and persist for years. The antibody 
profile of the sera is significantly different in patients with lethal disease as com-
pared to those that survived. This difference can serve as a prognostic marker for 
the management of the patient. It has been shown that deceased patients show 
a much lower or even absent antibody response compared with survivors [18]. 
During outbreaks, ELISA methods for the detection of specific viral antigens are 
highly useful and frequently applied. Because high titers of filovirus particles are 
present in the blood and tissues of patients at the early stage of illness, several 
ELISA systems have been developed to diagnose an acute infection. Currently ap-
plied assays use monoclonal antibodies against different viral proteins, e.g. VP40. 
These systems are able to provide the results within 30 min, without a need for 
electricity or sophisticated equipment.
Virus isolation in cell cultures is one of the very sensitive methods. Acute 
phase patient sera or postmortem tissue samples may be appropriate material 
for the virus isolation. Ebola virus is able to replicate in numerous cell lines and 
virus growth can be detected by cytopathic effect. Vero or Vero E6 cells have 
been commonly used for this purpose. Additionally it is also possible to use 
a fluorescently-labeled specific antibodies for confirmation of antigens in infected 
cells.
Electron microscopy has also been useful in identification and detection of 
viral infections [23]. Due to the very characteristic shapes of virus particles this 
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method is specific and rapid, but requires a large number of virus particles in 
a sample, specific and expensive equipment and trained personnel respectively.
The paraffin sections of autopsy material, particularly from the liver and spleen, 
due to the high condensation of antigens and viral particles, are useful in im-
munohistochemical assays with the use of specific polyclonal or monoclonal an-
tibodies. Formalin-fixed specimens are not infectious and may be sent without 
special precautions or refrigeration.
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